Stock Analysis

Biofrontera Second Quarter 2024 Earnings: €0.023 loss per share (vs €0.12 profit in 2Q 2023)

XTRA:B8FK
Source: Shutterstock
Advertisement

Biofrontera (ETR:B8FK) Second Quarter 2024 Results

Key Financial Results

  • Revenue: €3.49m (down 71% from 2Q 2023).
  • Net loss: €2.64m (down from €330.0k profit in 2Q 2023).
  • €0.023 loss per share (down from €0.12 profit in 2Q 2023).
earnings-and-revenue-history
XTRA:B8FK Earnings and Revenue History October 2nd 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Biofrontera shares are up 3.7% from a week ago.

Risk Analysis

Be aware that Biofrontera is showing 3 warning signs in our investment analysis and 2 of those can't be ignored...

Valuation is complex, but we're here to simplify it.

Discover if Biofrontera might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About XTRA:B8FK

Biofrontera

A biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally.

Flawless balance sheet and slightly overvalued.

Advertisement